375 results about "Bacteriocyte" patented technology

Disclosed are methods of producing eukaryotic disulfide bond-containing polypeptides in bacterial hosts, and compositions resulting therefrom. Co-expression of a eukaryotic foldase and a disulfide bond-containing polypeptide in a bacterial host cell is demonstrated. In particular embodiments, the methods have been used to produce mammalian pancreatic trypsin inhibitor and tissue plasminogen activator (tPA) in soluble, biologically-active forms, which are isolatable from the bacterial periplasm. Also disclosed are expression systems, recombinant vectors, and transformed host cells.

Disclosed are methods and compositions for producing heterologous disulfide bond containing polypeptides in bacterial cells. In preferred embodiments the methods involve co-expression of a prokaryotic disulfide isomerase, such as DsbC or DsbG and a gene encoding a recombinant eukaryotic polypeptide. Exemplary polypeptides disclosed include tissue plasminogen activator.

Large scale processes for producing high purity samples of biologically active molecules of interest from bacterial cells are disclosed. The methods comprise the steps of producing a lysate solution by contacting a cell suspension of said plurality of cells with lysis solution; neutralizing said lysate solution with a neutralizing solution to produce a dispersion that comprises neutralized lysate solution and debris; filtering the dispersion through at least one filter; performing ion exchange separation on said neutralized lysate solution to produce an ion exchange eluate; and performing hydrophobic interaction separation on said ion exchange eluate to produce a hydrophobic interaction solution. Further, provided are compositions comprising large scale amounts of plasmid DNA produced by the disclosed large scale processes.

The inventive method allows peptides or polypeptides to be exposed on the surface of gram-negative host bacteria using specific intimin-based anchor modules. Intimins with shortened carboxy terminals have been found to be particularly suitable anchor modules for passenger domains in the exterior E. coli cell membrane. According to the method, host bacteria are transformed using vectors, on which are located a fused nucleic acid sequence consisting of a sequence segment which codes for an intimin with a shortened carboxy terminal and a nucleic acid sequence segment which codes for the passenger peptide that is to be exposed. The invention permits a particularly large number of passenger domains to be exposed on the cell surface of the bacteria, without adversely affecting the viability of the bacteria.

The present invention relates generally to compositions, methods and kits for use in clarification and viscosity reduction of biological samples. More specifically, the invention relates to such compositions, methods and kits that are useful in the isolation of biological macromolecules from cells (e.g., bacterial cells, animal cells, fungal cells, viruses, yeast cells or plant cells) via lysis and one or more additional isolation procedures, such as one or more filtration procedures. In particular, the invention relates to compositions, methods and kits wherein biological macromolecules are isolated using a filter, where the pore size increases in the direction of sample flow. The compositions, methods and kits of the invention are suitable for isolating a variety of forms of biological macromolecules from cells. The compositions, methods and kits of the invention are particularly well-suited for rapid isolation of nucleic acid molecules from bacterial cells.

The present disclosure describes methods and systems for improving the expression of a properly folded, biologically active protein of interest in a cell free synthesis system. The methods and systems use a bacterial cell free extract having an active oxidative phosphorylation system, and include an exogenous protein chaperone. The exogenous protein chaperone can be expressed by the bacteria used to prepare the cell free extract. The exogenous protein chaperone can be a protein disulfide isomerase and / or a peptidyl-prolyl cis-trans isomerase. The inventors discovered that the combination of a protein disulfide isomerase and a peptidyl-prolyl cis-trans isomerase produces a synergistic increase in the amount of properly folded, biologically active protein of interest.

Existing methods of meningococcal OMV preparation involve the use of detergent during disruption of the bacterial membrane. According to the invention, membrane disruption is performed substantially in the absence of detergent. The resulting OMVs which retain important bacterial immunogenic components, particularly (i) the protective NspA surface protein, (ii) protein NMB2132 and (iii) protein NMB 1870. A Typical process involves the following steps: (a) treating bacterial cells in the substantial absence of detergent; (b) centrifuging the composition from step (a) to separate the outer membrane vesicles from treated cells and cell debris, and collecting the supernatant; (c) performing a high speed centrifugation of the supernatant from step (b) and collecting the outer membrane vesicles in a pellet; (d) re-dispersing the pellet from step (c) in a buffer; (e) performing a second high speed centrifugation in accordance with step (c), collecting the outer membrane vesicles in a pellet; (f) re-dispersing the pellet from step (e) in an aqueous medium.

The present invention relates to bacteriophages for use in the treatment or prophylaxis of bacterial infections, especially mucosal bacterial infections such as Helicobacter pylori infections. In particular, it relates to modified filamentous bacteriophages. e.g. M13 phages, for such use, which bacteriophages present at its surface a recombinant protein comprising: (i) a first component derived from a bacteriophage surface protein; and (ii) a second component comprising variable region sequences of an antibody to provide a bacterial antigen binding site, said second component rendering said bacteriophage capable of binding, to and thereby inhibiting growth of bacterial cells involved in the etiology of said infection.

The present invention discloses a method for producing a target substance using a coryneform bacterium comprising culturing a coryneform bacterium having an ability to produce the target substance in a medium, resulting in accumulation of the target substance in the medium or cells of the bacterium, and collecting the target substance from the medium or the cells of the bacterium. Also disclosed is a coryneform bacterium which is introduced with a methanol dehydrogenase gene and which has enhanced activities of hexulose phosphate synthase and phosphohexuloisomerase, and to which an ability to utilize methanol is imparted or which has enhanced ability to utilize methanol, and the medium contains methanol as a carbon source.

The present invention relates to vectors, host-vector combinations and processes for preparing stable fusion proteins consisting of a carrier protein and a passenger protein, where expression of the fusion proteins leads to exposure of the passenger domains on the surface of bacterial cells, especially Escherichia coli cells. If required, the passenger domains can be released into the medium by proteases, for example by selected host factors such as, for example, OmpT.

The invention relates to compositions for treating parasitic worm infections in a mammal. The composition includes an amount of intracellular components of lysed, beneficial, soil-inhabiting yeast cells sufficient to treat parasitic worm infections in a mammal; and / or an amount of whole or lysed soil-inhabiting bacteria cells, wherein the amount is sufficient to treat parasitic worm infections in a mammal, and optionally a pharmaceutically suitable carrier.

The present invention relates to a process for providing purified bacteria-containing concentrates, comprising at least the steps of adding an aqueous solution to a first bacteria-containing concentrate to provide a bacteria-containing suspension, wherein the volume of the added aqueous solution is in the range of 0.3 liters to 10 liters per liter of said first bacteria-containing concentrate; and concentrating said bacteria-containing suspension to provide a second bacteria-containing concentrate. Further, the present invention relates to the purified concentrates per se.

An optical biological detector is able to bind specific targeted bacterial cells by stamping an antibody grating pattern onto a silicon surface. The antibody grating alone produces insignificant optical diffraction, but upon immunocapture of the targeted cells, the optical phase change produces a diffraction pattern. Micro-contact printing provides a method for placing the antibody grating pattern directly onto a substrate surface with no additional processes or binding chemicals. Antibodies or other biologically active material may be stamped directly onto clean native oxide silicon substrates with no other chemical surface treatments. Direct binding of the antibodies to the silicon occurs in a way that still allows them to function and selectively bind antigen. The performance of the sensor was evaluated by capturing Escherichia coli O157:H7 cells on the antibody-stamped lines and measuring the intensity of the first order diffraction beam resulting from the attachment of cells. The diffraction intensity increases in proportion to the cell density bound on the surface.

Methods for the controlled activation of the reuterin-production machinery of Lactobacillus reuteri by adding glycerol and other substances during the manufacture of cell-cultures and keeping the produced reuterin in the bacterial cell during preservation and storage. In particular this invention relates to the manufacture of large amounts of L. reuteri that are loaded with reuterin, and the use of such loaded bacteria for applications such as prevention and treatment of diseases, for food applications and the like.

The present invention relates to a composition for the manufacture of a medicament comprising living or dead bacteria with controlled amounts of surface-coupled proteins or proteinaceous compounds and a method for the preparation of the composition. The bacterium provides a multivalent heterologous protein display vehicle that may be used in the manufacture of vaccines or medicaments for delivery via the mucosa.

The present disclosure provides a ready-to-use bio-electrode stable for long term storage and a process of constructing the same. The process for construction of bio-electrode for electro-biocatalysis comprising of: selection of an electro-active bacteria; enrichment of said electro-active bacteria in a nutrient rich medium; separation of said electro-active bacterial cells from said nutrient rich medium; selection of an electrode material; surface modification of said electrode material; layering the surface modified electrode material with conductive material; layering the surface modified electrode material with an electro-active bacterial cells along with biofilm inducing agents and stabilizing agents; conditioning the electro-active bacterial cells layered electrode; incubating the electrode obtained with an immobilizing agent along with conductive material; and conditioning the electrode with micronutrients to obtain a bio-electrode.

The invention relates to a process for the production of L-amino acids, in which the following steps are carried out: a) fermentation of the coryneform bacteria producing the desired L-amino acid, in which at least the mqo gene is attenuated, b) concentration of the desired L-amino acid in the medium or in the cells of the bacteria, and c) isolation of the L-amino acid, and, optionally, bacteria are used in which further genes of the biosynthesis pathway of the desired L-amino acid are additionally enhanced, or bacteria are used in which at least some of the metabolic pathways reducing formation of the desired L-amino acid are excluded.

Methods for increasing the resistance to rumen inactivation of a cultured Gram positive bacteria strain useful for gastrointestinal delivery of bioactive compounds to ruminants, which includes the steps of growing a culture of the bacteria strain through at least one passage in a growth medium containing an amount of lysozyme effective to induce the growth of bacterial cell walls resistant to protozoal predation; and recovering the bacteria strain from the lysozyme-containing medium. Rumen-bypass feed supplements produced by the inventive method are also disclosed, as well as methods for supplementing the diet of a ruminant with the rumen bypass feed supplements and an in vitro method for evaluating the resistance of Gram positive bacteria strains to rumen inactivation in vivo.

The invention belongs to the field of biological medicine, and particularly relates to composite hydrogel for promoting wound healing as well as a preparation method and application thereof. The composite hydrogel is composed of gelatin, antibacterial photodynamic peptide and recombinant human III-type collagen. A photosensitizer Ce6 is introduced for photodynamic antibacterial chemotherapy antibiosis, and the photosensitizer Ce6 generates active oxygen under laser irradiation to cause microbial molecule oxidation and bacterial cell damage and death, so that the photosensitizer Ce6 and antibacterial peptide generate a synergistic effect. The antibacterial composite hydrogel has high biocompatibility, keeps a wet environment around a wound surface, can stably convey loaded antibacterial photodynamic peptide and recombinant human collagen to the surface of the wound, guides fibroblasts to migrate and proliferate and increases deposition of new collagen on blood vessels for reconstructionin a dermal repair process, thereby accelerating wound healing, thereby improving wound healing quality.

The present invention provides a recombinant gram-negative bacterial cell, characterized in that the cell comprises a recombinant polynucleotide encoding DsbC and has reduced Tsp protein activity compared to a wild-type cell.

The invention is directed compositions and methods related to bacterial cells that are physically associated with ceramide-like glycolipids for use as antigen carriers for heterologous antigens. The invention further relates to methods of incorporating ceramide-like glycolipid to bacterial cell walls. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.

This invention relates to a bacterial membrane agent and methods therefore. The membrane bacterial strain is labeled by color fluorescent protein gene. The said agent and methods verify in-situ analysis, i.e., analyzing under a condition of non-destructing biologic membrane; easy operation, i.e., no need of microbe culture and counting or extraction of cell nucleic acid for cross-breed or electrophoretic determination; and good real time online analysis.

The existing extraction and purification method of polyhydroxyalkanoate (PHA) comprises: adding hydrolase and the like into an organic solvent or a surfactant, and is complex and expensive in process.According to the invention, according to the method, a PHA-rich bacterial fermentation broth is treated with hot water or superheated water with a temperature of more than 100 DEG C so as to completewall breaking and purification of bacterial cells, and surfactant, protease and / or bleaching agent treatment and the like can also be combined to further improve the purity of PHA; and the method hasthe advantages of low cost, simple operation and high product recovery rate, and overcomes the problems of complex steps, high cost of addition of chemical substances, difficult treatment of downstream sewage and the like of the traditional PHA extraction.

PCT No. PCT / JP97 / 00991 Sec. 371 Date Jan. 6, 1999 Sec. 102(e) Date Jan. 6, 1999 PCT Filed Mar. 25, 1997 PCT Pub. No. WO97 / 35970 PCT Pub. Date Oct. 2, 1997An oligonucleotide is provided which has a nucleotide sequence derived from SEQ ID NO:1, characterized in that it contains at least one site capable of amplifying a nucleotide sequence characteristic of Vibrio parahaemolyticus. The oligonucleotide may have a nucleotide sequence not derived from SEQ ID NO:3, or incapable of amplifying nucleotide sequences originating in Vibrio alginolyticus and Vibrio harveyi, and may be represented by SEQ ID NO:5 or SEQ ID NO:6. A method of detecting Vibrio parahaemolyticus in a specimen is also provided which comprises preparing a primer set comprising two of the above oligonucleotides, selectively amplifying therewith a DNA gyrase subunit B gene sequence contained in the specimen as a target, and determining whether or not there is a gyrB unit specific for Vibrio parahaemolyticus in the specimen. Also provided is a primer which reacts specifically with a gyrB gene of Vibrio parahaemolyticus to thereby differentiate and identify the same among other Vibrios and strains other than the genus Vibrio. The Vibrio parahaemolyticus-specific primer serves to detect 285-bp gyrB gene fragments specific for this Vibrio by the PCR method without the necessity for DNA extraction or like operations from bacterial cells.

Isolated nucleic acid sequences and amino acid sequences for soluble, β-N-acetylglucosaminidase or active fragments or variants thereof which promote detachment of bacterial cells from a biofilm are provided. An isolated mutant bacteria which forms biofilm colonies which tightly adhere to surface but which are unable to release cells into the medium or spread over the surface is also provided. In additions, methods are described for modulating detachment of bacterial cells from biofilm by mutating soluble,β-N-acetylglucosamimidase or altering its expression or activity are also provided. Also provided are compositions, methods and devices for preventing, inhibiting and treating bacterial infections.